Skip to main content
Fig. 3 | BMC Rheumatology

Fig. 3

From: Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia

Fig. 3

Rapid monitoring of visits to a physician following launch of the Biosimilars Initiative. Cumulative incidence of first (A), second (B), third (C) and fourth (D) visits to a physician, and first (E) and second (F) visits to a rheumatologist during one year of follow-up. Periods with likelihood ratios of 7.1 or higher are shaded. Likelihood ratios were not estimated during the first 31 days of follow-up due to instability in likelihood ratios caused by small numbers

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us